FrancophonIA/ELRC3.0 huggingface dataset:
English: A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Cuprior therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Estonian: Sõltuvalt imetamise kasulikkusest lapsele ja ravi kasulikkusest naisele tuleb otsustada, kas lõpetada imetamine või katkestada ravi Cuprioriga või ravi Cuprioriga üldse mitte alustada.
English: Cuprior 150 mg
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Cuprior 150 mg
English: It is unknown whether trientine is excreted in human milk.
Estonian: Ei ole teada, kas trientiin eritub rinnapiima.
English: Serious iron deficiency anaemia and severe colitis may occur during treatment.
Estonian: Ravi ajal võib tekkida raske rauapuudusaneemia ja raske koliit.
English: Since copper is required for proper growth and mental development, dose adjustments may be required to ensure that the foetus will not become copper deficient and close monitoring of the patient is essential (see section 4.4).
Estonian: Vaske on vaja õige kasvuiibe ja vaimse arengu tagamiseks, mistõttu on vajalik ravimi annuse kohandamine selliselt, et lootel ei tekiks vasepuudust.
English: What you need to know before you take Cuprior 3.
Estonian: 1. Mis ravim on Cuprior ja milleks seda kasutatakse 2. Mida on vaja teada enne Cupriori võtmist 3.
English: The combination of trientine with zinc is not recommended.
Estonian: Trientiini ja tsingi koos kasutamine ei ole soovitatav.
English: It may also attach to copper in the gut and so reduce the amount taken up into the body.
Estonian: Ravim võib vasega seonduda ka sooles ja vähendada imenduva vase hulka.
English: The starting dose would usually correspond to the lowest dose in the range and the dose should subsequently be adapted according to the patient's clinical response (see section 4.4).
Estonian: Edaspidi peab annust kohandama lähtuvalt patsiendi kliinilisest reageerimisest ravile (vt lõik 4.4).
English: Colloidal anhydrous silica.
Estonian: Kolloidne veevaba ränidioksiid Glütserooldibehenaat
English: Unabsorbed trientine is eliminated through faecal excretion.
Estonian: Imendumata trientiin eritatakse roojaga.
English: EXP
Estonian: Tootja
English: Breast-feeding
Estonian: - Iiveldus
English: Lot
Estonian: Talk
English: Strength Pharmaceutical Form Route of administration Packaging Content (concentration) Package size
Estonian: Pakendi sisu (kontsentratsioon)
English: If treatment is stopped for any reason, the dose should be decreased gradually.
Estonian: Kui ravi mis tahes põhjusel katkestatakse, tuleb annust vähendada järk-järgult.
English: It is available as tablets (0.088, 0.18, 0.35, 0.7 and 1.1 mg).
Estonian: Seda turustatakse tablettidena (0,088 mg, 0,18 mg, 0,35 mg, 0,7 mg ja 1,1 mg).
English: The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated.
Estonian: Annust suurendatakse iga 5-7 ööpäeva järel, kuni sümptomid alluvad ravile ning ravim ei põhjusta talumatuid kõrvalnähte.
English: The maximum daily dose is three 1.1 mg tablets.
Estonian: Suurim annus on kolm 1,1 mg tabletti ööpäevas.
English: The full EPAR for Pramipexole Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Pramipexole Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The starting dose is one 0.088 mg tablet three times a day.
Estonian: Algannus on üks 0,088 mg tablett kolm korda ööpäevas.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pramipexole Accord on 30 September 2011.
Estonian: Euroopa Komisjon andis Pramipexole Accordi müügiloa, mis kehtib kogu Euroopa Liidus, 30. septembril
English: Pramipexole Accord can be used either on its own or in combination with levodopa (another medicine for Parkinson's disease), at any stage of disease including the later stages when levodopa starts becoming less effective.
Estonian: Pramipexole Accordi tohib kasutada ainsa ravimina või koos levodopaga (samuti Parkinsoni tõve ravim) haiguse mis tahes staadiumis, sealhulgas hilistes staadiumides, mil levodopa efektiivsus hakkab vähenema.
English: Dopamine is a messenger substance in the parts of the brain that control movement and co-ordination.
Estonian: Dopamiin on virgatsaine aju osades, mis juhivad liigutusi ja koordinatsiooni.
English: In patients with Parkinson's disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
Estonian: Parkinsoni tõvega patsientidel hakkavad dopamiini tootvad rakud hävima ja dopamiini kogus ajus väheneb.
English: What measures are being taken to ensure the safe and effective use of Pramipexole Accord?
Estonian: Mis meetmed võetakse, et tagada Palonosetron Accordi ohutu ja efektiivne kasutamine?
English: For more information about treatment with Pramipexole Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Pramipexole Accord toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson's disease, such as shaking, stiffness and slowness of movement.
Estonian: Pramipeksool stimuleerib aju samamoodi kui dopamiin, et patsient saaks juhtida liigutusi ning et väheneksid Parkinsoni tõve nähud ja sümptomid, näiteks värin, jäikus ja liigutuste aeglus.
English: Because Pramipexole Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pramipexole Accord on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pramipexole Accord.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Pramipexole Accord pramipexole
Estonian: Pramipexole Accord pramipeksool
English: Other information about Pramipexole Accord
Estonian: Muu teave Pramipexole Accordi kohta
English: The CHMP concluded that, in accordance with EU requirements, Pramipexole Accord has been shown to have comparable quality and to be bioequivalent to Mirapexin.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pramipexole Accord võrdväärne kvaliteet ja bioekvivalentsus ravimiga Mirapexin.
English: The Committee recommended that Pramipexole Accord be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi Pramipexole Accord müügiloa.
English: This means that Pramipexole Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Mirapexin.
Estonian: See tähendab, et Pramipexole Accord on sarnane võrdlusravimiga Mirapexin, millel juba on Euroopa Liidus müügiluba.
English: Therefore, the CHMP's view was that, as for Mirapexin, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Mirapexini korral, ületab ravimi Pramipexole Accord kasulikkus sellega kaasnevad riskid.
English: Pramipexole Accord is a ‘generic medicine'.
Estonian: Pramipexole Accord on geneeriline ravim.
English: Pramipexole Accord is a medicine that contains the active substance pramipexole.
Estonian: Pramipexole Accord on ravim, mis sisaldab toimeainena pramipeksooli.
English: The active substance in Pramipexole Accord, pramipexole, is a dopamine agonist (a substance that imitates the action of dopamine).
Estonian: Pramipexole Accordi toimeaine pramipeksool on dopamiini agonist (aine, millel on dopamiiniga analoogne toime).
English: Because Pramipexole Accord is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Mirapexin.
Estonian: Et Pramipexole Accord on geneeriline ravim, piirdusid uuringud katsetega, milles näidati ravimi Pramipexole Accord bioekvivalentsust võrdlusravimiga Mirapexin.
English: Pramipexole Accord must be given less often in patients who have problems with their kidneys.
Estonian: Neeruprobleemidega patsientidele tuleb Pramipexole Accordi manustada harvemini.
English: This is a summary of the European public assessment report (EPAR) for Pramipexole Accord.
Estonian: See on ravimi Pramipexole Accord Euroopa avaliku hindamisaruande kokkuvõte.
English: Pramipexole Accord is used to treat the symptoms of Parkinson's disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Estonian: Parkinsoni tõbi on progresseeruv ajuhäire, mis põhjustab värinat, liigutuste aeglust ja lihasjäikust.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pramipexole Accord have been included in the summary of product characteristics and the package leaflet.
Estonian: Pramipexole Accordi omaduste kokkuvõttesse ja pakendi infolehele lisati ravimi ohutu ja tõhusa kasutamise teave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What is Pramipexole Accord?
Estonian: Mis on Pramipexole Accord?
English: Why has Pramipexole Accord been approved?
Estonian: Miks Pramipexole Accord heaks kiideti?
English: How does Pramipexole Accord work?
Estonian: Kuidas Pramipexole Accord toimib?
English: How has Pramipexole Accord been studied?
Estonian: Kuidas Pramipexole Accordi uuriti?
English: What are the benefits and risks of Pramipexole Accord?
Estonian: Milles seisneb Pramipexole Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How is Pramipexole Accord used?
Estonian: Kuidas Pramipexole Accordi kasutatakse?
English: What is Pramipexole Accord used for?
Estonian: Milleks Pramipexole Accordi kasutatakse?
English: 20 mg/ml Oral drops, solution
Estonian: 20 mg/ml Suukaudsed tilgad, lahus pudel (klaas)
English: Leptospira vaccine
Estonian: Leptospira vaktsiin
English: 1 L. interrogans serogroup Canicola serovar Portland-vere (strain Ca-12-000), L interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Ic-02-001), L. interrogans serogroup Australis serovar Bartislava (strain As-05-073), L. kirscheneri serogrop Grippotyphosa serovar Dadas (strain Gr-01-005)).
Estonian: 1 Liigi L. interrogans serorühma Canicola serovar Portland-vere (tüvi Ca-12-000), liigi L interrogans serorühma Icterohaemorrhagiae serovar Copenhageni (tüvi Ic-02-001), liigi L. interrogans serorühma Australis serovar Bartislava (tüvi As-05-073), liigi L. kirscheneri serorühma Grippotyphosa serovar Dadas (tüvi Gr-01-005).
English: The first injection can be given from six to nine weeks of age and the second four weeks later.
Estonian: Esimese süsti tohib teha 6-9 nädala vanuses ja teine 4 nädalat hiljem.
English: This summary was last updated on 16 July 2012.
Estonian: Kokkuvõtte viimane uuendus: 16/07/2012.
English: The company has presented data from both laboratory and field studies to establish the safety and effectiveness of the vaccine, including how long it took for the dogs to be fully protected and how long the vaccine could provide protection.
Estonian: Tootja esitas vaktsiini ohutuse ja efektiivsuse tõendamiseks nii labori- kui ka väliuuringute andmed, sealhulgas andmed selle kohta, kui kiiresti täielik kaitse tekib ja kui kaua püsib.
English: The main infection source is from urine or urine-contaminated water or soil.
Estonian: Infektsioon saadakse peamiselt uriinist või uriiniga saastunud veest või mullast.
English: Leptospirosis disease in dogs results in bleeding, hepatitis (infection of the liver) and jaundice (yellowing of the skin and eyes) or nephritis (kidney infection).
Estonian: Leptospiroos põhjustab koertel verejookse, hepatiiti (maksapõletikku) ja ikterust (naha ja silmamunade kollasust) või nefriiti (neerupõletikku).
English: It contains four inactivated (killed) strains of Leptospira bacteria.1.
Estonian: See sisaldab Leptospira bakteri nelja inaktiveeritud (hävitatud) tüve1.
English: An occasional temporary, acute (short-term) hypersensitivity (allergic) reaction may occur.
Estonian: Mõnel loomal võib esineda ajutine ja lühiajaline ülitundlikkusreaktsioon (allergia).
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Nobivac L4 on 16 July 2012.
Estonian: Euroopa Komisjon andis vaktsiini Nobivac L4 müügiloa, mis kehtib kogu Euroopa Liidus, 16/07/2012.
English: They also showed that the vaccine is safe to give to pregnant bitches.
Estonian: Samuti näitasid uuringud, et vaktsiin on ohutu tiinetele koertele.
English: The studies showed that the vaccine reduces infection with Leptospira and excretion of the bacteria into the urine.
Estonian: Uuringud näitasid, et vaktsiin vähendab Leptospira bakterite tekitatud infektsiooni ja bakterite eritumist uriini.
English: The benefit/risk balance can be found in the scientific discussion module of this EPAR.
Estonian: Vaktsiini kasulikkuse ja riski suhe on käesoleva Euroopa avaliku hindamisaruande teadusliku arutelu kokkuvõttes.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobivac L4 exceed the risks and recommended that it be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et vaktsiini Nobivac L4 kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: The vaccine also reduces the excretion (shedding) of the virus into the urine by the infected dogs, thereby reducing the risk of transmission.
Estonian: Vaktsiin vähendab bakterite eritumist (ülekandumist) nakatunud koerte uriini, vähendades infektsiooni levimise riski.
English: A mild and temporary increase in body temperature ( 1°C) may occur for a few days after vaccination, with some puppies showing less activity and/or a reduced appetite.
Estonian: Pärast vaktsineerimist võib mõneks päevaks kehatemperatuur veidi tõusta (≤ 1 °C); mõnel kutsikal võib tekkida loidus ja/või väheneda söögiisu.
English: When puppies are known to have high levels of maternally derived antibodies (special type of proteins, received from the mother in the milk, that help the body to fight infection), it is recommended that the first vaccination is given at
Estonian: Kui on teada, et kutsikate organismis on rohkesti emapiimaga saadud antikehi (valgud, mis aitavad võidelda infektsiooniga), on soovitatav teha esimene süst 9 nädala vanuses.
English: In future if the animals are exposed to the bacteria the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad hiljem nende bakteritega uuesti kokku, tekivad antikehad kiiremini.
English: Nobivac L4 is used to vaccinate dogs from six weeks of age to reduce the risk of developing an infection with certain Leptospira strains.
Estonian: Vaktsiini Nobivac L4 kasutatakse vähemalt 6-nädalaste koerte vaktsineerimiseks, et vähendada Leptospira teatud tüvedest põhjustatud infektsiooni (nakkuse) riski.
English: When Nobivac L4 is given to dogs, the immune system recognises the bacteria contained in the vaccine as ‘foreign' and makes defences against them.
Estonian: Kui koertele manustatakse vaktsiini Nobivac L4, peab immuunsüsteem vaktsiinis sisalduvaid baktereid võõraks ja tekitab nende vastu antikehi.
English: Nobivac L4 is a vaccine.
Estonian: Nobivac L4 on vaktsiin.
English: The vaccine is given to dogs as two injections, four weeks apart, under the skin.
Estonian: Vaktsiini manustatakse koerale 2 nahaaluse süstina, teine süst tehakse 4 nädalat pärast esimest.
English: Nobivac L4 is a vaccine available as a suspension for injection.
Estonian: Nobivac L4 on vaktsiin, mida turustatakse süstesuspensioonina.
English: Why has Nobivac L4 been approved?
Estonian: Miks Nobivac L4 heaks kiideti?
English: Other information about Nobivac L4:
Estonian: Muu teave vaktsiini Nobivac L4 kohta
English: What is Nobivac L4?
Estonian: Mis on Nobivac L4?
English: How does Nobivac L4 work?
Estonian: Kuidas Nobivac L4 toimib?
English: What is the risk associated with Nobivac L4?
Estonian: Mis riskid vaktsiiniga Nobivac L4 kaasnevad?
English: What is Nobivac L4 used for?
Estonian: Milleks vaktsiini Nobivac L4 kasutatakse?
English: What benefit has Nobivac L4 shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Nobivac L4 kasulikkus?
English: EU/1/09/601/001 Firdapse
Estonian: EU/1/09/601/001
English: 10 mg tablet
Estonian: 10 mg Tablett
English: Perforated unit dose thermoformed blisters
Estonian: Ühikannuste kaupa perforeeritud ja termoformeeritud blisterpakendid
English: Packsize
Estonian: Firdapse
English: (invented) name Strength Pharmaceutical form
Estonian: Tugevus Ravimvorm Manustamistee Sisepakendi iseloomustus
English: MA (EU)-number
Estonian: Müügiloa nr Euroopa Liidus
English: g n d
Estonian: Pakendi suurus l n a
English: Other medicines and Zarzio
Estonian: Muud ravimid ja Zarzio
English: It is advisable to wait and see how you feel after taking Zarzio and before driving or operating machinery.
Estonian: Soovitatav on oodata ja vaadata, kuidas te tunnete ennast pärast Zarzio saamist ja enne auto juhtimist või masinate käsitsemist.
English: Zarzio can be used:
Estonian: Zarzio't saab kasutada:
English: How long will I have to take Zarzio?
Estonian: Kui kaua ma pean Zarzio't saama?
English: Contents of the pack and other information What Zarzio contains
Estonian: Pakendi sisu ja muu teave Mida Zarzio sisaldab
English: Accidental freezing will not harm Zarzio.
Estonian: Juhuslik külmumine ei kahjusta Zarzio't.
English: 1995 - 2000b a Analysis includes studies involving BM transplant during this period; some studies used GM-CSF b Analysis includes patients receiving BM transplant during this period
Estonian: 1995-2000b 2110 a Analüüs hõlmab luuüdi transplantaadi uuringuid sel perioodil, mõnes uuringus kasutati GM-CSF-i b Analüüs hõlmab luuüdi transplantaadiga patsiente sel perioodil.
English: If you become pregnant during Zarzio treatment, please inform your doctor.
Estonian: Kui rasestute Zarzio-ravi ajal, teatage sellest oma arstile.
English: What Zarzio looks like and contents of the pack
Estonian: Kuidas Zarzio välja näeb ja pakendi sisu
English: You will need to take Zarzio until your white blood cell count is normal.
Estonian: Te peate saama Zarzio't seni, kuni teie vere valgeliblede arv normaliseerub.
English: Zarzio is a white blood cell growth factor (granulocyte colony stimulating factor) and belongs to a group of proteins called cytokines.
Estonian: Zarzio on vere valgeliblede kasvufaktor (granulotsüütide kolooniat stimuleeriv faktor) ja kuulub valkude rühma, mida nimetatakse tsütokiinideks.
English: How is Zarzio given and how much should I take?
Estonian: Kuidas Zarzio't manustatakse ja kui palju ma pean seda kasutama?
English: Zarzio is not recommended during pregnancy.
Estonian: Zarzio't ei ole soovitatav kasutada raseduse ajal.
English: Zarzio is provided with or without a needle safety guard and you will be shown how to use this by your doctor or nurse.
Estonian: Zarzio't turustatakse koos nõelakaitsega või ilma ning teie arst või õde näitab teile, kuidas seda kasutada.
English: Please tell your doctor before starting treatment if you have: - osteoporosis (bone disease); - sickle cell anaemia, as Zarzio may cause sickle cell crisis.
Estonian: Rääkige oma arstile enne ravi alustamist, kui teil on: - osteoporoos (luuhaigus); - sirprakuline aneemia, sest Zarzio võib põhjustada sirprakulise aneemia kriisi.
English: Zarzio may have a minor influence on your ability to drive and use machines.
Estonian: Zarzio võib mõjutada kergelt teie autojuhtimise ja masinate käsitsemise võimet.
English: Your doctor will tell you how much Zarzio you should take.
Estonian: Teie arst ütleb, kui palju Zarzio't te peate saama.
English: In view of the possible risk of microbial contamination, Zarzio syringes are for single use only.
Estonian: Bakteriaalse saastumise riski vähendamiseks on Zarzio süstlid mõeldud ainult ühekordseks kasutamiseks.
English: This section contains information on how to give yourself an injection of Zarzio.
Estonian: Selles lõigus leiate teavet selle kohta, kuidas Zarzio't endale ise süstida.
English: If you forget to use Zarzio
Estonian: Kui te unustate Zarzio't kasutada
English: Zarzio is a biosimilar medicinal product.
Estonian: Zarzio on bioloogiliselt sarnane ravimpreparaat.
English: If you have missed an injection, or injected too little, contact your doctor as soon as possible.
Estonian: Kui teil jäi Zarzio süstimata või süstisite seda liiga vähe, võtke ühendust oma arstiga niipea kui võimalik.
English: What you need to know before you use Zarzio Do not use Zarzio
Estonian: Mida on vaja teada enne Zarzio kasutamist Ärge kasutage Zarzio't
English: Inject the Zarzio solution as you have been shown by your doctor.
Estonian: Süstige Zarzio lahus nii, nagu arst on teile näidanud.
English: If required, Zarzio may be diluted in glucose 50 mg/ml (5%) solution.
Estonian: Vajaduse korral võib Zarzio't lahjendada 50 mg/ml (5%) glükoosilahuses.
English: Zarzio is available in packs containing 1, 3, 5 or 10 pre-filled syringes with injection needle and with or without a needle safety guard.
Estonian: Zarzio't turustatakse pakendites, mis sisaldavad 1, 3, 5 või 10 süstlit koos süstenõelaga ja nõelakaitsega või ilma.
English: Your doctor will tell you how long you will need to take Zarzio.
Estonian: Teie arst ütleb, kui kaua te peate Zarzio't saama.
English: Zarzio has not been tested in pregnant or breast-feeding women.
Estonian: Zarzio't ei ole uuritud rasedatel ega imetavatel naistel.
English: A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zarzio therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Estonian: Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine tuleb otsustada, arvestades imetamise kasu lapsele ja ravi kasu naisele.
English: Zarzio containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
Estonian: Zarzio's sisalduv r-metHuG-CSF (filgrastiim) põhjustab 24 tunni jooksul märkimisväärset neutrofiilide ja vähemal määral monotsüütide arvu tõusu perifeerses veres.
English: Randomised, double-blind, single and multiple dose, crossover studies in 204 healthy volunteers showed that the pharmacokinetic profile of Zarzio was comparable to that of the reference product after subcutaneous and intravenous administration.
Estonian: Randomiseeritud, topeltpimedas, ühekordse ning mitme annusega tehtud ristuvas uuringus, kus osales 204 tervet vabatahtlikku, oli Zarzio farmakokineetiline profiil subkutaansel ja intravenoossel manustamisel võrreldav referentspreparaadiga.
English: Zarzio is usually given as a daily injection into the tissue just under the skin (known as a subcutaneous injection).
Estonian: Zarzio't manustatakse tavaliselt iga päev süstena otse nahaalusesse koesse (tuntud subkutaanse süstena).
English: If you use more Zarzio than you should
Estonian: Kui te kasutate Zarzio't rohkem kui ette nähtud
English: What Zarzio is and what it is used for
Estonian: Mis ravim on Zarzio ja milleks seda kasutatakse
English: Do not administer Zarzio to patients with a history of hypersensitivity to filgrastim or pegfilgrastim.
Estonian: Ärge manustage Zarzio't patsientidele, kellel on esinenud ülitundlikkust filgrastiimi või pegfilgrastiimi suhtes.
English: If you develop or are likely to develop cancers of the blood, you should not use Zarzio unless instructed by your doctor.
Estonian: Kui teil tekib verevähk või on selle tekkimine tõenäoline, ei tohi te Zarzio't kasutada, v.a juhul, kui arst nii ütleb.